Araim Pharmaceuticals, Ossining, New York 10562, USA.
Mol Med. 2012 May 9;18(1):486-96. doi: 10.2119/molmed.2011.00414.
Tissue injury, hypoxia and significant metabolic stress activate innate immune responses driven by tumor necrosis factor (TNF)-α and other proinflammatory cytokines that typically increase damage surrounding a lesion. In a compensatory protective response, erythropoietin (EPO) is synthesized in surrounding tissues, which subsequently triggers antiinflammatory and antiapoptotic processes that delimit injury and promote repair. What we refer to as the sequelae of injury or disease are often the consequences of this intentionally discoordinated, primitive system that uses a "scorched earth" strategy to rid the invader at the expense of a serious lesion. The EPO-mediated tissue-protective system depends on receptor expression that is upregulated by inflammation and hypoxia in a distinctive temporal and spatial pattern. The tissue-protective receptor (TPR) is generally not expressed by normal tissues but becomes functional immediately after injury. In contrast to robust and early receptor expression within the immediate injury site, EPO production is delayed, transient and relatively weak. The functional EPO receptor that attenuates tissue injury is distinct from the hematopoietic receptor responsible for erythropoiesis. On the basis of current evidence, the TPR is composed of the β common receptor subunit (CD131) in combination with the same EPO receptor subunit that is involved in erythropoiesis. Additional receptors, including that for the vascular endothelial growth factor, also appear to be a component of the TPR in some tissues, for example, the endothelium. The discoordination of the EPO response system and its relative weakness provide a window of opportunity to intervene with the exogenous ligand. Recently, molecules were designed that preferentially activate only the TPR and thus avoid the potential adverse consequences of activating the hematopoietic receptor. On administration, these agents successfully substitute for a relative deficiency of EPO production in damaged tissues in multiple animal models of disease and may pave the way to effective treatment of a wide variety of insults that cause tissue injury, leading to profoundly expanded lesions and attendant, irreversible sequelae.
组织损伤、缺氧和显著的代谢应激会激活先天免疫反应,这些反应由肿瘤坏死因子 (TNF)-α 和其他促炎细胞因子驱动,通常会增加病变周围的损伤。作为一种代偿性保护反应,促红细胞生成素 (EPO) 在周围组织中合成,随后触发抗炎和抗细胞凋亡过程,限制损伤并促进修复。我们所说的损伤或疾病的后遗症通常是这个故意不协调的、原始系统的结果,它使用“焦土”策略来清除入侵物,而不惜以严重的损伤为代价。EPO 介导的组织保护系统依赖于受体表达,这种表达受炎症和缺氧的调节,具有独特的时空模式。组织保护受体 (TPR) 通常不由正常组织表达,但在损伤后立即变得具有功能。与在即时损伤部位内强大且早期的受体表达形成对比,EPO 的产生是延迟的、短暂的且相对较弱。减轻组织损伤的功能性 EPO 受体与负责红细胞生成的造血受体不同。根据目前的证据,TPR 由β共同受体亚基 (CD131) 与参与红细胞生成的相同 EPO 受体亚基组成。其他受体,包括血管内皮生长因子的受体,在某些组织(例如内皮细胞)中似乎也是 TPR 的组成部分。EPO 反应系统的失调及其相对较弱为外源性配体的干预提供了机会。最近,设计了一些分子,这些分子优先激活仅 TPR,从而避免激活造血受体的潜在不利后果。在给药时,这些药物在多种疾病动物模型中成功替代了受损组织中相对缺乏的 EPO 产生,并且可能为广泛的损伤引起的组织损伤开辟了有效的治疗方法,导致广泛的病变和随之而来的不可逆后遗症。